Table 1.
Cohort demographics and plasma biomarker values
| Cohort 1 (N = 37) | Cohort 2 (N = 94) | Cohort 3 (N = 121) | Cohort 4 (N = 26) | Cohort 5 (N = 96) | Cohort 6 (N = 40) | All Cohorts (N = 414) | |
|---|---|---|---|---|---|---|---|
| Age | |||||||
| Mean (SD) | 73.1 (7.8) | 71.1 (8.0) | 66.1 (7.8) | 75.1 (6.8) | 71.4 (7.6) | 69.7 (9.1) | 70.0 (8.3) |
| Min | 59.2 | 56.7 | 47.0 | 66.1 | 45.0 | 46.1 | 45.0 |
| Max | 87.5 | 93.1 | 85.0 | 88.9 | 89.0 | 86.0 | 93.1 |
| Sex | |||||||
| Male (%) | 54.1% | 58.5% | 23.1% | 57.7% | 40.6% | 35% | 41.3% |
| Amyloid Positive (%) | 49% | 46% | 17% | 42% | 49% | 52% | 39% |
| CDR | |||||||
| Percent CDR = 0 [N] | - [0] | 50% [94] | - [0] | 56% [25] | - [0] | 75% [40] | 57.2% [159] |
| MMSE | |||||||
| Percent MMSE = 27–30 [N] | 45.9% [37] | - [0] | 100% [121] | 64% [25] | - [0] | 85% [40] | 84.3% [223] |
| Biomarker Used to Determine Brain Amyloid Status (% participants) | |||||||
| PiB | – | – | 68% | 54% | – | 52% | 28% |
| Amyvid | – | – | 32% | – | 22% | 48% | 19% |
| Neuraceq | – | – | – | – | 78% | – | 18% |
| CSF ELISA | – | 100% | – | – | – | – | 23% |
| CSF IPMS | 100% | – | – | 46% | – | – | 12% |
| ApoE Proteotype | |||||||
| E2/E3 (%) | 5.4% | 8.5% | 5.0% | 23.1% | 7.3% | 7.5% | 7.7% |
| E2/E4 (%) | 2.7% | 6.4% | – | – | 2.1% | 5.0% | 2.7% |
| E3/E3 (%) | 51.4% | 46.8% | 47.9% | 46.2% | 52.1% | 45.0% | 48.6% |
| E3/E4 (%) | 29.7% | 28.7% | 29.8% | 19.2% | 34.4% | 35.0% | 30.4% |
| E4/E4 (%) | 10.8% | 9.6% | 17.4% | 11.5% | 4.2% | 7.5% | 10.6% |
| C2N Plasma Aβ42/40 | |||||||
| Mean (SD) | 0.089 (0.012) | 0.102 (0.010) | 0.101 (0.009) | 0.096 (0.009) | 0.087 (0.009) | 0.100 (0.009) | 0.097 (0.011) |
| Min | 0.065 | 0.084 | 0.080 | 0.082 | 0.059 | 0.080 | 0.059 |
| Max | 0.113 | 0.148 | 0.126 | 0.114 | 0.113 | 0.117 | 0.148 |
No patients had the E2/E2 genotype. Cohort 2 used Heparin tubes whereas all other cohorts used EDTA tubes for blood collection. [N] is the number of participants where data was available/provided
CSF cerebrospinal fluid, ELISA enzyme-linked immunoassay, IPMS immunoprecipitation-mass spectrometry, CDR Clinical Dementia Rating, MMSE Mini-Mental State examination